Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab versus adalimumab plus methotrexate in rheumatoid arthritis after inadequate response to one TNF inhibitor
NL-OMON36590Phase 3Withdrawn
- Sponsor
- Roche
- Start
- Oct 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tocilizumab, adalimumab and methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: Clinical remission by DAS28 at week 24. Planned start Oct 2011; status: withdrawn.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON36590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36590.